It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.
SILVER SPRING, Md.-- United Therapeutics Corp. said Tuesday that the U.S. Food and Drug Administration declined its application for an extended-release tablet version of its pulmonary arterial hypertension drug treprostinil.
Printing off a kidney or another human organ may sound like something out of science fiction, but with advancements in 3D printing technology, the idea may not be so far-fetched.
Cramer makes the call on viewers' favorite stocks.
Shares of Michael Kors spiked Tuesday, as the luxury retailer reported a 47 percent increase in fiscal third-quarter earnings.
In breaking news CNBC's Scott Cohn says a former Nasdaq employee has pled guilty to securities fraud for insider trading.
The S&P may reach the 1,400 to 1,430 level between now and the end of May, said Michael McGervey, president of McGervey Wealth Management. He explained his thinking to CNBC.
It appears the biotech news flow is heating up. But should you get in before year's end?
Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?
2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.
Following are the day’s biggest winners and losers. Find out why shares of Las Vegas Sands and Colgate-Palmolive popped while Abercrombie & Fitch and Alcoa dropped.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
The first days of the New Year bring Citigroup's Citi Investment Research Top Picks: The bank polled each of its fundamental analysts on a single best money-making idea for 2008, with the option of an additional small-cap pick. Citi says its 2007 list produced an average share price return of 16.7 percent, well ahead of the Standard and Poor's 500 average of 4.2 percent.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.